{"id":"ibi343-gemcitabine-albumin-bound-paclitaxel","safety":{"commonSideEffects":[{"rate":"30%","effect":"Neutropenia"},{"rate":"20%","effect":"Anemia"},{"rate":"15%","effect":"Thrombocytopenia"},{"rate":"40%","effect":"Nausea"},{"rate":"30%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL3039516","moleculeType":"Small molecule","molecularWeight":"527.65"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Gemcitabine is a chemotherapy medication used to treat various types of cancer, including breast, ovarian, pancreatic, and non-small cell lung cancer. It works by inhibiting DNA synthesis, which ultimately leads to cell death.","oneSentence":"Gemcitabine is a nucleoside analog that inhibits DNA synthesis by interfering with DNA polymerase.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:50:44.208Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer"},{"name":"Ovarian cancer"},{"name":"Pancreatic cancer"},{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT07483554","phase":"PHASE2","title":"IBI343 in Combination Therapy for Advanced Malignant Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2026-03-25","conditions":"CLDN18.2 Positive, Gastric/Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma","enrollment":389},{"nctId":"NCT07415525","phase":"PHASE2","title":"IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang University","startDate":"2026-02-01","conditions":"Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma","enrollment":40},{"nctId":"NCT06770439","phase":"PHASE2","title":"IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2025-04-18","conditions":"Advanced Pancreatic Cancers","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"IBI343,Gemcitabine, Albumin-bound Paclitaxel","genericName":"IBI343,Gemcitabine, Albumin-bound Paclitaxel","companyName":"Innovent Biologics (Suzhou) Co. Ltd.","companyId":"innovent-biologics-suzhou-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gemcitabine is a nucleoside analog that inhibits DNA synthesis by interfering with DNA polymerase. Used for Breast cancer, Ovarian cancer, Pancreatic cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}